首页 | 本学科首页   官方微博 | 高级检索  
     

慢性肾脏病患者低分子肝素抗氧化作用的研究
引用本文:刘晓燕,钟一红,丁小强. 慢性肾脏病患者低分子肝素抗氧化作用的研究[J]. 中国血液净化, 2011, 10(3): 129-132. DOI: 10.3969/j.issn.1671-4091.2011.03.004
作者姓名:刘晓燕  钟一红  丁小强
作者单位:1. 200032,上海,复旦大学附属中山医院肾内科;116027,大连,大连医科大学附属第医院肾内科
2. 复旦大学附属中山医院肾内科,上海,200032
基金项目:教育部国家重点学科211二期重大项目,上海市科学技术委员会重人科技攻关项目
摘    要:目的 阐明在慢性肾脏病(chronic kidney disease,CKD)时低分f肝素是否具有抗氧化作用,为临床治疗提供理论依据.方法 选取CKD 3~5期住院患者40例,随机分为低分子肝素(low mo-lecular weight heparin,LMWH)组(速碧体0.4ml/d皮曰卜射,连续10d)及还原型谷胱甘肽(reducedglutathione,GSH)组(泰特1.8g/d加入0.9%NaC1溶液静脉滴注,连续10d).测定2组用药前后血浆氧化应激指标谷胱甘肽氧化物酶(glutathione peroxidase,GSH-PX)、丙二醛(malondialdehyde,MDA)、晚期氧化蛋白产物(advanced oxidation protein products,AOPP),并观察药物不良反应.结果 LMWH及GSH治疗后血浆AOPP水平均显著降低(P<0.05),GSH组AOPP降低值显著高于LMWH组,分别为(4.89±0.66)nmo1/l,和(2.86±0.82)nmol/L,差异有统计学意义(P<0.05);LMWH及GSH治疗后GSH-PX活力均显著升高(P<0.05),LMWH组和GSH组GSH-PX升高值分别为(3.55±1.01)X10~4U/L和(4.77±1.78)X10~4U/L,差异无统计学意义(P>0.05);LMWH治疗前后MDA分别为(5.54±1.66)nmo l/m1和(5.42±1.40)nmo1/ml,差异无统计学意义(P>0.05),GSH治疗后MDA活力比治疗前显著降低,分别为(5.09±1.44)nmol/ml和(4.61±1.30)nmol/ml,差异有统计学意义(P<0.05).两组药物治疗期间均未见明显不良事件.结论 LMWH可以改善CKD患者氧化应激状态,短期应用未见明显不良反应.与GSH相比,LMWH的抗氧化作用稍弱.

关 键 词:氧化应激  慢性肾脏病  低分子肝素  还原型谷胱甘肽

The effect of low molecular weight heparin as an antioxidant in chronic kidney disease
LIU Xiao-yan,ZHONG Yi-hong,DING Xiao-qiang. The effect of low molecular weight heparin as an antioxidant in chronic kidney disease[J]. Chinese Journal of Blood Purification, 2011, 10(3): 129-132. DOI: 10.3969/j.issn.1671-4091.2011.03.004
Authors:LIU Xiao-yan  ZHONG Yi-hong  DING Xiao-qiang
Affiliation:1. 1Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai 200032, China; 2Department of Nephrology, the Second Affiliated Hospital of Dalian Medical University, Dalian 116027, China
Abstract:Objective To identify the anti-oxidative effect of low molecular weight heparin (LMWH) in chronic kidney disease (CKD). Method Forty CKD patients at stage 3-5 were randomly divided into two groups, glutathione (GSH) group (0.9% NaCl 250ml + Glutathione 1.8g/d, intravenous injection for 10 days) and LMWH group (Fraxiparine 0.4ml/d, subcutaneous injection for 10 days). Plasma malondialdehyde (MDA), advanced oxidation protein product (AOPP) and glutathione peroxidase activity (GSH-PX) were measured at the beginning and the end of glutathione or LMWH administration. Results Plasma AOPP decreased and plasma GSH-PX increased significantly after the treatment in both LMWH and GSH groups (P0.05). The decrease of plasma AOPP was more significant in GSH group than in LMWH group (2.86±0.82 vs. 4.89±0.66μmol/l, P0.05). After the treatment, plasma MDA did not change significantly in LMWH group, but decreased (5.09±1.44 vs. 4.61±1.30nmol/ml, P0.05) in GSH group. There were no apparent side effects in both groups. Conclusion LMWH ameliorates oxidative stress state without apparent side effects. The anti-oxidative effect of LMWH is slightly lower than that of GSH.
Keywords:Oxidative stress  Chronic kidney disease  Low molecular weight heparin  Reduced glutathione
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号